Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience

IF 0.3 Q4 ONCOLOGY Oncology in Clinical Practice Pub Date : 2023-05-09 DOI:10.5603/ocp.2023.0020
Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen
{"title":"Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience","authors":"Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen","doi":"10.5603/ocp.2023.0020","DOIUrl":null,"url":null,"abstract":"Introduction. Neoadjuvant chemotherapy for HER2-positive breast cancer consists of a chemotherapy regimen plus trastuzumab with or without pertuzumab. The use of trastuzumab has been shown to improve pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Purposes: To evaluate the efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in the treatment of HER2-positive breast cancer in Vietnamese patients. Material and methods. This retrospective study reviewed stage II–III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) at the Vietnamese National Cancer Hospital. The primary endpoint was the pCR rate which was defined as the absence of invasive tumor in the breast and axil - lary nodes (ypT0/is, ypN0). The secondary endpoints were DFS, OS, and toxicities. Results. The complete and partial clinical response of 51 patients were 33.3% and 58.8%, respectively. The pCR rate was 41.2%; there was a significantly higher response in cT1-2 patients compared to cT3-4 ones (61.1% vs. 39.3%, p = 0.033). Three-year estimated DFS and OS rates were 81.3% and 93.0%, respectively. Treatment was generally well tolerated. Grade 3/4 neutropenia and anemia were uncommon (21.6% and 7.8%). No symptomatic cardiac dysfunction occurred. Conclusions. Neoadjuvant TCH, non-anthracycline chemotherapy with single anti-HER2 regimen achieved high efficacy, with a good pCR rate and favorable tolerability in stage II or III HER2-positive breast cancer patients.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"20 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Neoadjuvant chemotherapy for HER2-positive breast cancer consists of a chemotherapy regimen plus trastuzumab with or without pertuzumab. The use of trastuzumab has been shown to improve pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Purposes: To evaluate the efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in the treatment of HER2-positive breast cancer in Vietnamese patients. Material and methods. This retrospective study reviewed stage II–III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) at the Vietnamese National Cancer Hospital. The primary endpoint was the pCR rate which was defined as the absence of invasive tumor in the breast and axil - lary nodes (ypT0/is, ypN0). The secondary endpoints were DFS, OS, and toxicities. Results. The complete and partial clinical response of 51 patients were 33.3% and 58.8%, respectively. The pCR rate was 41.2%; there was a significantly higher response in cT1-2 patients compared to cT3-4 ones (61.1% vs. 39.3%, p = 0.033). Three-year estimated DFS and OS rates were 81.3% and 93.0%, respectively. Treatment was generally well tolerated. Grade 3/4 neutropenia and anemia were uncommon (21.6% and 7.8%). No symptomatic cardiac dysfunction occurred. Conclusions. Neoadjuvant TCH, non-anthracycline chemotherapy with single anti-HER2 regimen achieved high efficacy, with a good pCR rate and favorable tolerability in stage II or III HER2-positive breast cancer patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多西紫杉醇、卡铂和曲妥珠单抗新辅助治疗后her2阳性浸润性乳腺癌的病理完全缓解和生存:越南经验
介绍。her2阳性乳腺癌的新辅助化疗包括化疗方案加曲妥珠单抗加或不加帕妥珠单抗。曲妥珠单抗已被证明可改善病理完全缓解(pCR)、无病生存期(DFS)和总生存期(OS)。目的:评价多西他赛、卡铂和曲妥珠单抗(TCH)治疗越南her2阳性乳腺癌患者的疗效和安全性。材料和方法。这项回顾性研究回顾了在越南国立肿瘤医院接受新辅助多西他赛、卡铂和曲妥珠单抗治疗的II-III期her2阳性乳腺癌患者。主要终点是pCR率,定义为乳腺和腋淋巴结无浸润性肿瘤(ypT0/is, ypN0)。次要终点为DFS、OS和毒性。结果。51例患者临床完全缓解率为33.3%,部分缓解率为58.8%。pCR率为41.2%;cT1-2患者的反应明显高于cT3-4患者(61.1% vs. 39.3%, p = 0.033)。3年估计DFS和OS率分别为81.3%和93.0%。治疗总体耐受良好。3/4级中性粒细胞减少症和贫血少见(21.6%和7.8%)。无症状性心功能障碍发生。结论。新辅助TCH、非蒽环类化疗单抗her2方案对II期或III期her2阳性乳腺癌患者疗效高,pCR率好,耐受性好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
期刊最新文献
Immunochemotherapy in patients with non-squamous lung cancer Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy Systemic treatment in triple-negative breast cancer patients — standard and novel approaches Tumor heterogeneity and its impact on sotorasib response in a patient with non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1